Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving plastic degrading enzymes via directed evolution.
Joho Y, Vongsouthi V, Gomez C, Larsen JS, Ardevol A, Jackson CJ. Joho Y, et al. Among authors: larsen js. Protein Eng Des Sel. 2024 Jan 29;37:gzae009. doi: 10.1093/protein/gzae009. Protein Eng Des Sel. 2024. PMID: 38713696 Free PMC article. Review.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto ÁJ, Uemura H, Ye DW, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Chowdhury S, et al. Among authors: larsen js. Future Oncol. 2024 Mar;20(10):563-578. doi: 10.2217/fon-2023-0649. Epub 2023 Dec 21. Future Oncol. 2024. PMID: 38126311 Review.
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Chowdhury S, et al. Among authors: larsen js. Ann Oncol. 2023 May;34(5):477-485. doi: 10.1016/j.annonc.2023.02.009. Epub 2023 Feb 27. Ann Oncol. 2023. PMID: 36858151 Free article. Clinical Trial.
Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
Eefsen RL, Larsen JS, Klarskov LL, Altaf R, Høgdall E, Ingeholm P, Lykke J, Nielsen DL, Pfeiffer P, Poulsen LØ, Qvortrup C, Schou JV, Mau-Sørensen M, Østerlind K, Jensen BV. Eefsen RL, et al. Among authors: larsen js. Int J Cancer. 2023 May 15;152(10):2145-2152. doi: 10.1002/ijc.34420. Epub 2023 Jan 18. Int J Cancer. 2023. PMID: 36594580
Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer.
Ladekarl M, Rasmussen LS, Kirkegård J, Chen I, Pfeiffer P, Weber B, Skuladottir H, Østerlind K, Larsen JS, Mortensen FV, Engberg H, Møller H, Fristrup CW. Ladekarl M, et al. Among authors: larsen js. Acta Oncol. 2022 Mar;61(3):277-285. doi: 10.1080/0284186X.2021.2012252. Epub 2021 Dec 8. Acta Oncol. 2022. PMID: 34879787
80 results